E
CORT icon

Ergoteles’s Corcept Therapeutics CORT Stock Holding History

Ergoteles’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-46,489
Closed -$1.11M – 1610
2022
Q2 		$1.11M Sell
46,489
-5,860
-11% -$128K 0.03% 506
2022
Q1 		$1.18M Sell
52,349
-26,449
-34% -$563K 0.04% 382
2021
Q4 		$1.56M Buy
78,798
+68,660
+677% +$1.39M 0.06% 311
2021
Q3 		$200K Sell
10,138
-18,171
-64% -$380K 0.01% 1005
2021
Q2 		$623K Buy
+28,309
New +$630K 0.01% 696

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ergoteles's CORT Position: Q3 2022 in Review

Ergoteles sold out of Corcept Therapeutics (CORT) in Q3 2022, closing a stake of 46,489 shares — an estimated $1.11M sold.

Ergoteles first reported a position in CORT in Q2 2021 and held it in 5 quarters. The position peaked at $1.56M in Q4 2021. 238 funds tracked by Wall St. Rank hold CORT as of Q3 2022.

  • Ergoteles reported no remaining Corcept Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 46,489 Corcept Therapeutics shares in Q3 2022, an estimated $1.11M.
  • Ergoteles first reported a position in Corcept Therapeutics in Q2 2021 and held it in 5 quarters.
  • Ergoteles's Corcept Therapeutics position peaked at $1.56M in Q4 2021.
  • 238 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.